Abizer Gaslightwala - 23 Jun 2025 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)

Role: President & CEO, Director
Signature: /s/ Torsten Hombeck, as Attorney-in-Fact
Issuer symbol: AKTX
Transactions as of: 23 Jun 2025
Net transactions value: +$7,120
Form type: 4
Filing time: 25 Jun 2025, 16:30:04 UTC
Previous filing: 24 Jun 2025
Next filing: 29 Aug 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Gaslightwala Abizer	President & CEO, Director	C/O AKARI THERAPEUTICS PLC, 22 BOSTON WHARF ROAD FL 7, BOSTON	/s/ Torsten Hombeck, as Attorney-in-Fact	25 Jun 2025	0002049375

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKTX	American Depositary Shares representing Ordinary Shares	Purchase	$1,084	+943	+0.35%	$1.15	272,371	23 Jun 2025	Direct	F1
transaction	AKTX	American Depositary Shares representing Ordinary Shares	Purchase	$6,035	+5,203	+1.9%	$1.16	277,574	24 Jun 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.
F2	The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.15 to $1.16, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in this footnote.

Content

Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.15 to $1.16, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in this footnote.